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Myeloid-derived suppressor cells (MDSCs) (CD33+CD11b+) 
are a heterogenous population derived from immature 
myeloid cells consisting of two main subsets: CD15+CD66b+ 
granulocytic (G-MDSCs) and CD14+HLA-DR– monocytic 
(M-MDSCs) cells (1). G-MDSCs consist of relatively 
immature and pathologically activated neutrophils, whereas 
M-MDSCs are inflammatory monocytes (2). While 
MDSCs are associated with a poor clinical outcome in 
cancer, their role in chronic inflammatory diseases remains 
unclear probably because, among other explanations, the 
heterogeneity of this cellular population. 
Systemic lupus erythematosus (SLE) is a disorder of 
largely unknown etiology whose pathogenesis can affect 
almost all organs and tissues. SLE is characterized by an 
autoimmune response with circulating autoantibodies 
secreted by B cells, which are aided by the CD4+ T cell 
subset, follicular helper T (Tfh) cells. A growing body 
of evidence in both human and murine studies confirm 
a pivotal role for IL17-secreting T-cells (Th17) cells in 
the progression of SLE disease [see (3) for a review] (4). 
Indeed, lupus-prone mice are partially protected from 
immunopathology by a reduction in renal Th17 cell 
accumulation (5). Therefore, modulation of Th17 
cell migration and trafficking to inflamed organs is an 
attractive therapeutic option for reducing disease-related 
inflammation. However, the precise mechanism of Th17 
cell accumulation in damaged SLE organs remains unclear. 
Yang and colleagues team demonstrated that the 
percentage of blood MDSCs is positively correlated with the 
SLE disease activity index (SLEDAI) in patients. Moreover, 
this team observed that IL-6 accumulation in SLE 
patients promotes the expression of arginase-1 (Arg-1) by 
G-MDSCs. Arg-1 enzymatically hydrolyzes the amino acid 
L-arginine (L-Arg) to ornithine and urea. Unexpectedly, 
while L-Arg depletion by MDSCs in tumors is responsible 
for the suppression of  the immune response (1) , 
this depletion in SLE patients causes inflammation by 
activating two kinases, general control nondepressible 2 
(GCN2) and mTOR, through a molecular mechanism that 
depends on the increase in uncharged tRNA (6) and that 
triggers Th17 differentiation. Indeed, MDSCs promote 
Th17 development in vitro when co-cultured with naive 
healthy autologous CD4 T-cells. This effect is abrogated 
in the presence of the Arg-1 inhibitor, nor-NOHA. Using 
the same experimental set-up, Wu et al. demonstrated that 
MDSCs derived from SLE patients amplify the positive 
effect of co-culture on Th17 differentiation, again in an 
Arg-1-dependent manner. Using a humanized mouse 
model, in which injection of PBMCs from SLE patients 
into immunodeficient mice (NOD/SCID) gives rise to 
SLE-like disease, they showed an in vivo role for MDSC 
and Arg-1. Indeed, prior depletion of MDSCs from PBMCs 
or nor-NOHA-mediated inhibition of Arg-1 halts the 
development of disease and expression of il-17a in both the 
spleen and kidney. Strikingly, in their hands, MDSCs would 
appear to exacerbate the pathological role of Th17 cells in 
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SLE patients. This study emphasizes that although MDSCs 
block T-cell proliferation in lupus and cancer, these cells can 
also promote the differentiation of IL17-expressing CD4+ 
T-cells, fueling inflammation in lupus patients. Taking into 
account that IL-17 is known to promote the production of 
IL-6 and directly recruits MDSC in tumor environment (7), 
one can envision that Wu et al. highlighted an amplification 
loop that might cause acceleration of the pathogenesis in 
SLE patients.
A mechanistic link between MDSC, Arg-1 and Th17 
cells has recently been reported (8). Indeed, Iwata et al. 
observed an increased number of MDSCs (CD11b+GR-
1low) in SLE patients and the percentage of these cells was 
correlated with the progression of the disease. Nonetheless, 
they did not evaluate the impact of MDSCs on T-cell 
differentiation but instead showed that the increased 
Arg-1 activity in these myeloid cells was responsible for 
the inhibition of T-cell proliferation in lupus-prone mice 
MRLLpr. These differences in the effects of Arg-1 on SLE 
outcome and progression could be due to the lupus-prone 
mouse models used in these studies—adoptive cell transfer 
in Wu et al., versus genomic mutation in the CD95 loci in 
Iwata et al.—or could be reconciled because disparate degrees 
of proliferation account for Th cell differentiation (9). A more 
established role for Arg-1 in suppression of Th2 function in 
vivo (10) and in promoting intracellular T. gondii survival 
have already been described (11).
Our group recently demonstrated that the tumour 
necrosis factor (TNF) member, CD95L (also known as 
FasL or CD178) aggravates the inflammatory process 
in SLE patients by recruiting Th17 cells in inflamed 
organs (12). The CD95L receptor, namely CD95 (also 
known as Fas), belongs to the death domain (DD)—
containing members of TNF receptor superfamily (13). 
Regardless of accumulating evidence indicating that 
this plasma membrane receptor possesses non-apoptotic 
functions, CD95 is still considered as a death receptor (14). 
CD95L is expressed as a transmembrane “cytokine” 
(m-CD95L), whose extracellular domain is composed of a 
juxtamembrane stalk region and a TNF homology domain. 
This stalk region can be cleaved by metalloproteases (15) 
releasing a soluble CD95L into the bloodstream. In 
presence of m-CD95L, CD95 aggregates and forms a 
molecular complex consisting of FADD and caspase-8/10 
that is called death-inducing signaling complex (DISC) (16). 
Metalloprotease-cleaved CD95L [cl-CD95L for cleaved 
CD95L to distinguish this ligand from its soluble, exosome-
bound counterpart (17,18)] fails to form DISC but triggers 
non-apoptotic signaling pathways such as NF-κB (19) and 
PLCγ1-driven Ca2+ response (20). In a pathophysiological 
standpoint, we showed that this soluble ligand, cl-CD95L, 
is accumulated in sera of lupus patients and promotes 
endothelial transmigration of activated T lymphocytes 
through the formation of a molecular complex designated 
MISC for motility-inducing signaling complex (20). 
Binding of cl-CD95L to CD95 triggers the recruitment of 
PLCγ1 and the implementation of a Ca2+ signal promoting 
the endothelial transmigration of Th17 cells (12). PLCγ1 
recruitment occurs at the level of the juxtamembrane region 
of CD95, designated calcium-inducing domain (CID). 
A selective inhibitor consisting of the cell-penetrating 
domain of TAT fused to CID, namely TAT-CID, interacts 
with PLCγ1 and prevents its recruitment to endogenous 
CD95. Moreover, injection of TAT-CID in lupus-prone 
mice (MRLLpr/+) blocks endothelial transmigration of Th17 
cells and alleviates clinical symptoms. In this study, we did 
not investigate the effect of TAT-CID on the recruitment 
of MDSC cells in spleen and kidney of the lupus-prone 
mice MRLLpr/−. According to the study of Wu et al., it 
would be interesting to address whether TAT-CID by 
preventing endothelial transmigration of Th17, could also 
inhibit the accumulation of MDSCs in damaged organs of 
lupus-prone mice indicating that either Th17 recruitment 
precedes MDSC accumulation or cl-CD95L exacerbates 
inflammation in SLE patients by recruiting simultaneously 
Th17 and MDSCs initiating the local amplification loop 
of the inflammatory process in these organs. Like IL-6 and 
IL-17, we cannot rule out that cl-CD95L, which is also 
increased in these patients (20), contributes to MDSC and/
or Th17 differentiation in organs of SLE patients. Overall 
these findings raise the question whether MDSCs and cl-
CD95L are biomarkers of lupus flare by promoting Th17 
differentiation and trafficking, respectively. This question 
remains to be addressed to better understand the lupus 
etiology and propose novel and targeted treatments for 
clinicians to more efficiently treat this pathology. 
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